Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company

AstraZeneca Restructures County Oncology Team to Enhance Vertical Alignment

Fineline Cube Jun 18, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading global biopharmaceutical company, is planning to restructure and spin...

Company Drug

Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC

Fineline Cube Jun 18, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...

Company Drug

MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention

Fineline Cube Jun 18, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced...

Company Drug

Kintor Pharmaceutical Initiates Phase II Clinical Trial for Acne Treatment GT20029 in China

Fineline Cube Jun 18, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the enrollment...

Company Drug

RemeGen’s Telitacicept Receives NMPA Approval for Clinical Trial in IgG4 Related Diseases

Fineline Cube Jun 18, 2024

RemeGen (HKG: 9995), a Chinese pharmaceutical company, has announced that it has received clinical trial...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Breast Cancer Drug Combo

Fineline Cube Jun 18, 2024

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that it...

Company Deals

Shineco Partners with Tuling Vision to Develop Intelligent Healthcare Solutions

Fineline Cube Jun 18, 2024

Shineco Inc. (NSDQ: SISI), a U.S.-based company, has signed a partnership deal with China-headquartered Tuling...

Company Deals

Wuxi’s Binhu District Partners with Fresenius Kabi to Boost Healthcare Services

Fineline Cube Jun 18, 2024

The Binhu District People’s Government of Wuxi, Jiangsu province, China, has entered into a partnership...

Company Drug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Phase II Trial in Pancreatic Cancer

Fineline Cube Jun 18, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...

Company Drug

Walvax Biotechnology Halts COVID-19 Vaccine Clinical Trials Citing Low Benefits

Fineline Cube Jun 18, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors

Fineline Cube Jun 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Deals

Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development

Fineline Cube Jun 18, 2024

Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with...

Company Drug

BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US

Fineline Cube Jun 18, 2024

BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...

Company Drug

Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials

Fineline Cube Jun 18, 2024

Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...

Company Drug

Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US

Fineline Cube Jun 18, 2024

Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...

Company Drug

MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma

Fineline Cube Jun 18, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company

AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer

Fineline Cube Jun 17, 2024

Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...

Company Drug

FDA Approves Broadened Use of BMS’ Next-Gen TKI Augtyro for Advanced Solid Tumors

Fineline Cube Jun 17, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Deals

CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally

Fineline Cube Jun 17, 2024

CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced...

Company Deals

Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round

Fineline Cube Jun 17, 2024

Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed...

Posts pagination

1 … 345 346 347 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.